Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on ...

JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.

This week's dividend activity included increased payouts from Citigroup (NYSE:C) and Duke Energy (DUK) as well as ...

New emerging life sciences hubs are gaining ground amid the market shift.

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...

A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles ...

Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. Johnson & Johnson (NYSE:JNJ) has long been considered one of the most dependable dividend stocks, ...

An FDA advisory committee ruled in two separate votes that two belantamab mafodotin combination regimens should not be used ...

This month in the Zantac litigation, the Delaware Supreme Court tossed all the plaintiffs’ experts in thousands of cases, ...

The global clinical nutrition market is set to witness a growth rate of 7% in the next 5 years. Increasing aging population ...

Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy appeared at risk.